FDA Awards Breakthrough Device Designation to Powerful Medical for AI ECG Model

Powerful Medical’s PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), indicating PMcardio’s prowess in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention.

Every 40 seconds, someone in the United States has a heart attack,¹ and rapid diagnosis is crucial to saving heart muscle and preventing long-term damage, often leading to higher mortality rates. The ECG remains the primary tool for rapid diagnostics, yet the standard of care often fails to detect heart attacks accurately and timely, resulting in critical delays in treatment. PMcardio is reportedly the only solution capable of detecting both STEMI and STEMI equivalents on the ECG—aligning with the emerging emphasis on a paradigm shift towards Occlusion Myocardial Infarction (OMI) diagnosis and bridging a vital gap in early, precise heart attack diagnosis.

“For the last 20 years, life-saving treatment exists for heart attack patients, yet far too many still don’t receive the urgent care they need due to delays in diagnosis and inefficient triage,” Powerful Medical Chief Medical Officer Robert Herman, M.D., Ph.D., said. “This is especially critical in settings where immediate specialist evaluation isn’t available—only 17% of patients presenting to rural centers make it to the catheterization lab in time for intervention.² By equipping physicians and allied providers with an AI-powered tool for accurate and immediate STEMI detection, available around the clock, we can bridge this gap, ensure timely treatment, and improve patient outcomes, often preventing avoidable deaths.”

The FDA’s Breakthrough Device Designation provides PMcardio with an expedited review process and close collaboration with the agency on its path toward market authorization. This designation is reserved for technologies that offer significant advantages over existing solutions and address unmet medical needs.

The Breakthrough Device recognition underscores the FDA’s acknowledgment of Powerful Medical’s STEMI AI ECG Model, dubbed “Queen of Hearts,” to set a new standard in frontline heart attack detection and triage, ultimately enhancing care quality, accelerating treatment decisions, and saving lives through earlier and more accurate diagnosis.

“FDA Breakthrough Device Designation is a pivotal milestone in our effort to revolutionize heart attack detection and ensure every patient receives immediate, life-saving care,” Powerful Medical Chief Operating Officer Felix Bauer stated. 

With this designation, Powerful Medical not only works closely with the FDA on market approval but also gains improved access to CMS reimbursement mechanisms to bring the PMcardio STEMI AI ECG Model to healthcare providers nationwide.

“We’re committed to bringing this life-saving technology to the U.S., the largest healthcare market in the world. This recognition by the FDA validates the impact of our innovation and brings us closer to transforming emergency cardiac care on a global scale,” Powerful Medical CEo Martin Herman said.

Powerful Medical is a health technology company specializing in artificial intelligence-driven cardiovascular diagnostics. Its flagship product, PMcardio, harnesses AI to enhance ECG interpretation, streamline patient triage, and support clinical decision-making.

References
¹ Tsao, C.W., Aday, A.W., et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation. 2023.
² Jollis, J.G., Granger, C.B., et al. Treatment time and in-hospital mortality among patients with ST-segment elevation myocardial infarction. JAMA. 2018–2021.